The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2025 | Targeted agents and immunotherapies being explored in primary CNS lymphoma: BTKis & CAR T-cells
Lakshmi Nayak, MD, Dana-Farber Cancer Institute, Boston, MA, provides an overview of novel targeted agents and immunotherapies being investigated for the treatment of primary CNS lymphoma. Dr Nayak highlights the potential of BTK inhibitors (BTKis), including ibrutinib, tirabrutinib, and zanubrutinib, which have shown promising responses and durability of response. Dr Nayak then discusses the promise of CD19 and CD20-directed CAR T-cell therapy. This interview took place at the 13th Annual Meeting of the Society of Hematologic Oncology (SOHO 2025) in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
